glp-1 cardiovascular outcome trials Clinical Outcomes with Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled | Drugs fig1.png

It would be the first GLP-1based obesity therapy requiring only monthly injections

In effect, these mice make a quick recovery after stroke and, as a result, there is little chance that further improvement in recovery may be offered through pharmacological treatment

Phase 2 and phase 3 trials have also indicated that orforglipron, an oral, non-peptide GLP-1 receptor agonist, is associated with weight loss and improvement in cardiometabolic parameters in adults with obesity or in those with overweight status and at least one weight-related comorbidity, in the absence of diabetes [100,101]

The drug should emerge as a first-line therapy for persons with type 2 diabetes and associated overweight/obesity as well as atherosclerotic cardiovascular disease

Tamara Hannon, a pediatric endocrinologist with Indiana University and lead author of the recent tirzepatide trial for kids, tells Yahoo

The 2026 Aetna formulary explicitly lists Zepbound as non-formulary/not covered on Standard Plan and Advanced Control plans